Stockscreener 앱 받기
3.42
3.32%
0.11
전일 마감가:
$3.31
열려 있는:
$3.22
하루 거래량:
1.21M
Relative Volume:
0.81
시가총액:
$353.61M
수익:
$58.36M
순이익/손실:
$-25.72M
주가수익비율:
-9.393
EPS:
-0.3641
순현금흐름:
$-24.91M
1주 성능:
-3.93%
1개월 성능:
+49.34%
6개월 성능:
-5.26%
1년 성능:
+23.47%
1일 변동 폭
$3.22
$3.53
1주일 범위
$3.2003
$3.79
52주 변동 폭
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.42 | 353.61M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
164.33 | 75.76B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.87 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.20 | 46.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.99 | 20.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
283.35 | 14.70B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts - Defense World
Research Analysts Offer Predictions for AQST FY2026 Earnings - Defense World
Aquestive Therapeutics Holds Annual Stockholders Meeting - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Millennium Management LLC - Defense World
Two Sigma Advisers LP Takes $57,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Two Sigma Investments LP Buys 42,160 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wellington Management Group LLP Sells 5,579 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
BNP Paribas Financial Markets Sells 7,286 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Lifted by ProShare Advisors LLC - Defense World
Oppenheimer Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at Oppenheimer - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated at Oppenheimer - Defense World
Oppenheimer Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Analysts at Oppenheimer - Defense World
Aquestive Therapeutics (AQST) Receives Positive Coverage and Sets Future Milestones | AQST Stock News - GuruFocus
Deutsche Bank AG Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated by Analysts at Oppenheimer - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Oppenheimer - Defense World
Aquestive Therapeutics Prepares for FDA Approvals and Launches - TipRanks
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics - GuruFocus
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics | AQST Stock News - GuruFocus
Oppenheimer lowers Aquestive Therapeutics stock price target to $7 By Investing.com - Investing.com Canada
Oppenheimer Adjusts Price Target for Aquestive Therapeutics (AQST) | AQST Stock News - GuruFocus
Bank of America Corp DE Boosts Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Oppenheimer Adjusts Price Target for Aquestive Therapeutics (AQS - GuruFocus
D. E. Shaw & Co. Inc. Has $450,000 Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128% - Yahoo
Northern Trust Corp Has $2.14 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Insider Monkey
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World
AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st
Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST) - The Globe and Mail
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating fro - GuruFocus
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria
AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus
Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus
Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.54%
자본화:
|
볼륨(24시간):